Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug

Inclusion Criteria: * The patient's treatment must be in accordance with the local marketing authorization (MA) for Vimpat® * The decision to prescribe Vimpat® has to be made by the physician before and independently of his/her decision to include the patient in the study * The Vimpat® treatment should have been started not longer than 2 weeks before study inclusion of the patient * The patient must have a diagnosis of Epilepsy with Partial-Onset Seizures * Based on the physician's clinical judgment, the patient's seizure activity is not controlled sufficiently on a current monotherapy and it is in the patient's best interest to be prescribed adjunctive Vimpat® Exclusion Criteria: In accordance with the Summary of Product Characteristics (SmPC)